Riskpilot← Back to searchSign inGet full accessALTRAPHARMA Invest ApS
APSActiveCVR 34483884Storkevænget 9Engineering activities and related technical consultancy · NACE 7112Est. 20121 employees
Revenue 2025
DKK -89K
+107% vs 2024
EBITDA margin
122.2%
-153% vs 2024
Equity ratio
71.5%
Financial strength
Net profit 2025
DKK -85K
-198% vs 2024
| Revenue | DKK -89K | +107% |
| EBITDA | DKK -109K | -153% |
| Net profit | DKK -85K | -198% |
| Total assets | DKK 145K | -39% |
| Equity | DKK 104K | +17% |
| Employees | 1 | — |
Legal name
ALTRAPHARMA Invest ApS
CVR number
34483884
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
18. april 2012
Share capital
DKK 80.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen
Company purpose
Selskabets formål er konsulent og rådgivningsvirksomhed. Eje værdipapirer samt anden
formueanbringelse og driftsaktivitet. Eje og forvalte fast og løs ejendom samt al virksomhed,
som efter ledelsens skøn har forbindelse hermed.
Address
Storkevænget 9
Phone
+4531414104
Email
mt@altrapharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 817 | 1.374 | 1.396 | 843 | 1.154 | 473 | 149 | 158 | 527 | -76 | -172 | -67 | -43 | -89 |
| Staff expenses | -232 | -1.161 | -1.083 | -827 | -1.056 | -109 | -0 | -0 | -0 | -91 | -304 | -0 | -0 | -20 |
| EBITDA | 585 | 213 | 314 | 16 | 98 | 364 | 149 | 158 | 527 | -167 | -476 | -67 | -43 | -109 |
| Depreciation & amort. | -9 | -11 | -11 | -3 | -0 | -0 | -0 | -0 | -4 | -5 | -6 | -0 | -0 | -0 |
| EBIT | 576 | 201 | 302 | 14 | 98 | 364 | 149 | 158 | 524 | -171 | -482 | -67 | -43 | -109 |
| Net financials | -8 | -3 | -2 | -0 | -7 | -16 | -0 | -3 | -0 | -1 | -3 | -0 | 0 | 0 |
| Profit before tax | 568 | 198 | 301 | 14 | 91 | 348 | 149 | 155 | 524 | -173 | -486 | -67 | -43 | -109 |
| Tax | 144 | 53 | 77 | 7 | 23 | 78 | 46 | 46 | 117 | -27 | -1 | -0 | -129 | -24 |
| Net profit | 424 | 145 | 223 | 7 | 67 | 270 | 103 | 110 | 407 | -146 | -484 | -67 | 87 | -85 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 863 | 1.144 | 940 | 982 | 1.536 | 1.834 | 793 | 452 | 961 | 808 | 249 | 182 | 240 | 145 |
| Equity | 504 | 650 | 623 | 379 | 247 | 517 | 183 | 292 | 699 | 554 | 69 | 2 | 89 | 104 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 359 | 495 | 317 | 603 | 1.289 | 1.317 | 610 | 159 | 262 | 253 | 180 | 179 | 151 | 41 |
| Total debt | 359 | 495 | 317 | 603 | 1.289 | 1.317 | 610 | 159 | 262 | 253 | 180 | 179 | 151 | 41 |
EBITDA margin
-10866500.0%
This company
15.8%
Market median
-68775416% vs market
20122025
Equity ratio
71.5%
This company
38.2%
Market median
+87% vs market
20122025
Return on equity
-81.9%
This company
18.4%
Market median
-545% vs market
20122025
Net profit margin
-8494400.0%
This company
8.1%
Market median
-104869236% vs market
20122025
Asset turnover
-0.61×
This company
1.12×
Market median
-154% vs market
20122025
Debt / equity
0.40×
This company
0.62×
Market median
+35% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-07-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-07-01 – 2024-06-30
- Annual report 2023Filed via CVR / Virk · Period 2022-07-01 – 2023-06-30
- Annual report 2022Filed via CVR / Virk · Period 2021-07-01 – 2022-06-30
- Annual report 2021Filed via CVR / Virk · Period 2020-07-01 – 2021-06-30
- Annual report 2020Filed via CVR / Virk · Period 2019-07-01 – 2020-06-30
- Annual report 2019Filed via CVR / Virk · Period 2018-07-01 – 2019-06-30
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-06-30
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-04-18 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MT Management | Management | 2012 | — | — |
GA Management | Management | 2012 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ALTRA 14 ApS | Company | 66.7% | 66.7% | 2025 |
| Individual | 25.0% | 25.0% | 2025 | |
ETAG Holding ApS | Company | 50.0% | 50.0% | 2016 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ALTRA 14 ApS
ALTRAPHARMA Invest ApS Board members of ALTRAPHARMA Invest ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marianne Thrane | Management | 0 companies |
| Gitte Albert | Management | 0 companies |